Pegasys (pegylated interferon α -2a) / Roche |
NCT02604823: A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV) |
|
|
| Completed | 4 | 307 | RoW | Peginterferon alfa-2a, Pegasys | Hoffmann-La Roche | Hepatitis B, Chronic | 11/05 | 11/05 | | |
NCT00077649: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC). |
|
|
| Completed | 4 | 188 | US | ribavirin [Copegus], peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys] | Hoffmann-La Roche | Hepatitis C, Chronic | 12/05 | 12/05 | | |
NCT01120795: Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy |
|
|
| Completed | 4 | 55 | RoW | Pegylated interferon and ribavirin, Pegasys and Copegus | Melbourne Health, The University of New South Wales, St Vincent's Hospital, Sydney, Western Hospital, Australia, Monash University, Hoffmann-La Roche | Chronic Hepatitis C | 01/06 | 07/06 | | |
NCT00087568: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin |
|
|
| Completed | 4 | 57 | US | Ribavirin, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis C, Chronic | 03/06 | 03/06 | | |
NCT00077636: ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection. |
|
|
| Completed | 4 | 1469 | US, Canada, Europe, RoW | Copegus, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis C, Chronic | 03/06 | 03/06 | | |
NCT00087607: Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC). |
|
|
| Completed | 4 | 385 | US | Ribavirin, Copegus, Peginterferon alfa-2b (PEG-Intron), Rebetol, Peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis C, Chronic | 03/06 | 04/06 | | |
NCT00475072: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C. |
|
|
| Completed | 4 | 14 | RoW | peginterferon alfa-2a [Pegasys], ribavirin | Hoffmann-La Roche | Hepatitis C, Chronic | 07/06 | 07/06 | | |
NCT00087594: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program. |
|
|
| Completed | 4 | 48 | US | peginterferon alfa-2a [Pegasys], ribavirin | Hoffmann-La Roche | Hepatitis C, Chronic | 10/06 | 10/06 | | |
NCT00948220: Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C |
|
|
| Completed | 4 | 26 | Europe | peginterferon alfa-2a and ribavirin, Pegasys, Copegus | University of Ulm, Hoffmann-La Roche | Hepatitis C, Chronic, Liver Diseases, Virus Diseases | 01/07 | 03/08 | | |
NCT02570191: A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV) |
|
|
| Completed | 4 | 60 | Europe | Peginterferon alfa-2a, Pegasys | Hoffmann-La Roche | Hepatitis B, Chronic | 02/07 | 02/07 | | |
NCT00275548: Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C |
|
|
| Completed | 4 | 12 | US | Pegasys, peginterferon alfa-2a, Ro25-8310), Copegus, (ribavirin, Ro20-9963) | Mayo Clinic, Roche Pharma AG | Liver Transplant, Hepatitis C | 06/07 | 04/09 | | |
NCT02864199: A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment |
|
|
| Completed | 4 | 63 | US, Europe, RoW | Peginterferon alfa-2a, Pegasys, Ribavirin, Copegus | Hoffmann-La Roche | Hepatitis C, Chronic | 09/07 | 09/07 | | |
NCT00107653: Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1. |
|
|
| Completed | 4 | 569 | US | Ribavirin, Peginterferon alfa-2a | Hoffmann-La Roche | Hepatitis C, Chronic | 09/07 | 09/07 | | |
NCT00226382: Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment |
|
|
| Completed | 4 | 50 | RoW | Pegylated Interferon-alfa-2a | Chinese University of Hong Kong, Hoffmann-La Roche | Chronic Hepatitis B | 04/08 | 04/08 | | |
NCT00087646: REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy |
|
|
| Completed | 4 | 948 | US, Canada, Europe, RoW | Ribavirin, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis C, Chronic | 05/08 | 05/08 | | |
NCT02761629: Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus |
|
|
| Completed | 4 | 180 | RoW | Peg-Interferon Alpha-2A, Pegasys, Peg-IFN-Alpha-2A, Ribavirin | Hoffmann-La Roche | Hepatitis C, Chronic | 05/08 | 05/08 | | |
NCT01519921: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B. |
|
|
| Completed | 4 | 150 | RoW | peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 06/08 | 06/08 | | |
NCT01258101: A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3 |
|
|
| Completed | 4 | 395 | Europe | peginterferon alfa-2a [Pegasys], ribavirin | Hoffmann-La Roche | Hepatitis C, Chronic | 07/08 | 07/08 | | |
|
NCT02791269: A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program |
|
|
| Completed | 4 | 24 | RoW | Peginterferon alfa-2a, Pegasys | Hoffmann-La Roche | Hepatitis B, Chronic | 07/08 | 07/08 | | |
NCT00291616: Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B |
|
|
| Completed | 4 | 52 | RoW | Pegylated Interferon-alpha2a, Thymosin alpha1 & Pegylated Interferon-alpha2a | Seoul National University Hospital, Roche Pharma AG, SciClone Pharmaceuticals | Chronic Hepatitis B | 08/08 | 08/08 | | |
PHOENIX, NCT00087633: Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C. |
|
|
| Completed | 4 | 115 | US | peginterferon alfa-2a [Pegasys], Copegus | Hoffmann-La Roche | Hepatitis C, Chronic | 10/08 | 10/08 | | |
| Terminated | 4 | 42 | Europe | Fast initiation procedure | Haukeland University Hospital, Bergen Prison, Norwegian Correctional Service, Hoffmann-La Roche | Chronic Hepatitis C | 01/09 | 01/09 | | |
NCT00203606: Pegylated Interferon Plus Ribavirin in the Treatment of Active and Past Intravenous Drug Users Infected With Hepatitis C |
|
|
| Completed | 4 | 66 | Canada | pegylated interferon alfa-2a ( Roche) and ribavirin | University of Calgary, Canadian Institutes of Health Research (CIHR), Roche Pharma AG | Hepatitis c | 01/09 | 08/11 | | |
|
NCT00800748 / 2005-003932-23: A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C |
|
|
| Completed | 4 | 372 | Europe, RoW | Peginterferon alfa-2a, Pegasys, Ribavirin, Copegus | Hoffmann-La Roche | Hepatitis C, Chronic | 01/09 | 01/09 | | |
NCT00192647: A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection |
|
|
| Completed | 4 | 896 | Canada, RoW | PEG-IFN alfa-2a, Pegasys, Ribavirin, Copegus | Hoffmann-La Roche | Hepatitis C, Chronic | 03/09 | 03/09 | | |
NCT02598063: A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B |
|
|
| Completed | 4 | 255 | RoW | Adefovir dipivoxil, Lamivudine, Peginterferon alfa-2a, Pegasys | Hoffmann-La Roche | Hepatitis B, Chronic | 04/09 | 04/09 | | |
NCT00353418 / 2005-005506-23: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection |
|
|
| Completed | 4 | 415 | US | Peginterferon alfa-2a, Pegasys, Ribavirin, Copegus | Hoffmann-La Roche | Hepatitis C, Chronic | 04/09 | 04/09 | | |
NCT00394277 / 2005-005507-41: A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C |
|
|
| Completed | 4 | 1175 | US, Canada, Europe, RoW | peginterferon alfa-2a, Pegasys, Ribavirin, Copegus | Hoffmann-La Roche | Hepatitis C, Chronic | 04/09 | 04/09 | | |
|
NCT00207311: Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus |
|
|
| Completed | 4 | 30 | US | Xenical, Pegasys, Copegus, Xenical (orlistat), Pegasys (PEG-Interferon alpha-2a), Xenicare Program, Xenical placebo, Pegasys (Peg interferon alpha-2a) | Brooke Army Medical Center, Hoffmann-La Roche, The Geneva Foundation | Fatty Liver, Hepatitis C | 05/09 | 05/09 | | |
NCT01787279: An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B |
|
|
| Completed | 4 | 59 | RoW | Peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 05/09 | 05/09 | | |
NCT00575224: Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9 |
|
|
| Completed | 4 | 60 | US | Pegylated interferon and ribavirin, Pegasys and Copegus | Pacific Health Foundation, Hoffmann-La Roche | Chronic Hepatitis C, Asian Americans, Novel Genotypes, Treatment | 09/09 | 09/09 | | |
NCT00487747: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B. |
|
|
| Completed | 4 | 18 | RoW | peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 10/09 | 10/09 | | |
NCT00614471: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B. |
|
|
| Completed | 4 | 219 | RoW | Entecavir, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 10/09 | 10/09 | | |
NCT00940420: A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C |
|
|
| Completed | 4 | 2695 | RoW | Copegus (ribavirin), peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis C, Chronic | 11/09 | 11/09 | | |
RelapC, NCT00641654 / 2006-003409-18: Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and Ribavirin |
|
|
| Terminated | 4 | 75 | Europe | Pegylated interferon alfa-2a and ribavirin, Pegasys, Copegus | Göteborg University, Hoffmann-La Roche | Chronic Hepatitis C | 12/09 | 12/09 | | |
NCT00436163 / 2006-005370-49: A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B |
|
|
| Completed | 4 | 39 | Europe | Peginterferon alfa-2a, Pegasys® | Hoffmann-La Roche | Hepatitis B, Chronic | 05/10 | 05/10 | | |
NCT00245414: Trial of Pegasys® in Patients With Chronic Hepatitis C |
|
|
| Completed | 4 | 108 | Japan | Pegasys® | Chugai Pharmaceutical | Chronic Hepatitis C | 07/10 | 07/10 | | |
NCT00412334: SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1. |
|
|
| Completed | 4 | 104 | Europe | Copegus, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis C, Chronic | 09/10 | 09/10 | | |
|
NCT00435825 / 2006-000870-63: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB). |
|
|
| Completed | 4 | 551 | US, Europe, RoW | peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 12/10 | 12/10 | | |
NCT00545233: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance. |
|
|
| Completed | 4 | 155 | US | peginterferon alfa-2a [Pegasys], Pegasys, ribavirin [Copegus], Copegus, Pioglitazone, Actos | Hoffmann-La Roche | Hepatitis C, Chronic | 12/10 | 12/10 | | |
NCT00474955: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure. |
|
|
| Completed | 4 | 27 | RoW | peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis C, Chronic | 06/11 | 06/11 | | |
| Completed | 4 | 190 | Europe | Pegasys, Ribavirin, epoetin beta [NeoRecormon] | Hoffmann-La Roche | Anemia | 11/11 | 11/11 | | |
NCT00940485: A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B |
|
|
| Completed | 4 | 200 | RoW | entecavir, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 12/11 | 12/11 | | |
NCT00922779: A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C |
|
|
| Completed | 4 | 6661 | RoW | peginterferon alfa-2a [Pegasys], ribavirin | Hoffmann-La Roche | Hepatitis C, Chronic | 06/12 | 06/12 | | |
NCT01447420: A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) |
|
|
| Completed | 4 | 129 | RoW | peginterferon alfa-2a, ribavirin [Copegus] | Hoffmann-La Roche | Hepatitis C, Chronic | 11/12 | 11/12 | | |
NCT01086085: A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive |
|
|
| Completed | 4 | 265 | RoW | Adefovir, peginterferon alfa-2a [PEGASYS] | Hoffmann-La Roche, Major Science and Technology Special Project of China Eleventh Five-year | Hepatitis B, Chronic | 03/13 | 03/13 | | |
NCT01033448: A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response |
|
|
| Completed | 4 | 59 | RoW | COPEGUS, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis C, Chronic | 06/13 | 06/13 | | |
NCT01429792: A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) |
|
|
| Completed | 4 | 1013 | RoW | peginterferon alfa-2a [Pegasys], ribavirin [Copegus] | Hoffmann-La Roche | Hepatitis C, Chronic | 06/13 | 06/13 | | |
NCT02641379: A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) |
|
|
| Completed | 4 | 737 | Europe | Peginterferon alfa-2a, Pegasys, Ribavirin | Hoffmann-La Roche | Hepatitis C, Chronic | 11/13 | 11/13 | | |
NCT01585324 / 2011-001256-10: A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) |
|
|
| Completed | 4 | 30 | Europe | peginterferon alfa-2a [Pegasys], ribavirin [Copegus] | Hoffmann-La Roche | Hepatitis C, Chronic | 01/14 | 01/14 | | |
NCT01467492: Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C |
|
|
| Terminated | 4 | 121 | US | Telaprevir, Incivek, VX-950, Ribavirin, Copegus®, RBV, Pegylated Interferon Alfa-2a, Pegasys®, Peg-IFN-Alfa-2a | Vertex Pharmaceuticals Incorporated | Hepatitis C | 05/14 | 05/14 | | |
|
NCT01591460 / 2011-004810-41: A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C |
|
|
| Completed | 4 | 165 | Europe | boceprevir, peginterferon alfa-2a [Pegasys], ribavirin (Copegus] | Hoffmann-La Roche | Hepatitis C, Chronic | 06/14 | 06/14 | | |
NCT01405027: Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy |
|
|
| Completed | 4 | 197 | US | Educational Intervention, Peg-Intron, Pegasys, Victrelis, Pegylated interferon alfa 2B, Pegylated interferon alfa 2A, Boceprevir, Ribavirin, Patient education and management skills training | Chronic Liver Disease Foundation, SCRI Development Innovations, LLC, Merck Sharp & Dohme LLC | Chronic Hepatitis C, Genotype 1 | 07/14 | 07/14 | | |
|
NCT01277601 / 2010-024586-45: Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B |
|
|
| Completed | 4 | 751 | US, Canada, Europe, RoW | TDF, Viread®, Peg-IFN, Pegasys® | Gilead Sciences | Chronic Hepatitis B | 08/14 | 07/15 | | |
NCT00922207: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B |
|
|
| Completed | 4 | 280 | RoW | Adefovir, Entecavir, Placebo, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 09/14 | 09/14 | | |
NCT00927082: A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B |
|
|
| Completed | 4 | 383 | RoW | peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 11/14 | 11/14 | | |
NCT01179594: A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B. |
|
|
| Withdrawn | 4 | 0 | NA | entecavir, peginterferon alfa-2a [Pegasys], placebo | Hoffmann-La Roche | Hepatitis B, Chronic | 11/14 | 11/14 | | |
| Completed | 4 | 14 | RoW | TPV/PEG-IFN/RBV, Telaprevir brand name: INCIVO, Ribavirin brand name: COPEGUS, PEG-IFN brand name: PEGASYS | Kirby Institute, Janssen-Cilag Ltd. | Hepatitis C, Chronic | 11/15 | 01/16 | | |